Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05841550
Other study ID # OMC04
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 19, 2023
Est. completion date May 19, 2035

Study information

Verified date November 2023
Source Oslo University Hospital
Contact Hanne Norseth, MD
Phone 92847595
Email h.m.norseth@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test the safety, tolerability, and efficacy of TG01 vaccination in patients with KRAS or NRAS mutation on codon 12/13 mutation who has multiple myeloma or high-risk smoldering multiple myeloma. The main question it aims to answer are: Is TG01/QS-21 vaccination safe and tolerable for this patient group? Is TG01/QS-21 vaccination treatment efficient in this group in terms of increased overall response rate, overall survival rate, progression-free survival, and time til next treatment? Is there an immunological response to the vaccine? Participants will be given TG01/QS-21 vaccination treatment. Treatment consists of 12 doses of TG01/QS-21 vaccine given every two weeks in the first 12 weeks, followed by every eight weeks until week 52.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date May 19, 2035
Est. primary completion date May 19, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female patients = 18 years of age - RAS mutation (KRAS/NRAS codon 12/13 mutation) detected on archival or fresh bone marrow material with VariantPlex Myeloid Panel - Confirmed diagnosis of high-risk smoldering multiple myeloma (SMM) according to IMWG criteria (30) and high-risk criteria as listed up below OR confirmed diagnosis of multiple myeloma (MM) according to IMWG criteria and measurable disease following = 1 line of treatment - In patients with high-risk SMM at least 2 of 3 following abnormalities, based on laboratory data obtained at screening must be fulfilled: 1. Serum M-protein >20 g/L. 2. Serum involved/uninvolved FLC ratio >20. 3. BMPC >20%. OR presence of =10% BMPC and at least one of the following based on laboratory data obtained at screening: - Serum M-protein =30 g/L (If IgA, IgA =20g/L) - Serum involved/uninvolved FLC ratio =8 (but <100) - Abnormal PC immunophenotype (=95% of BMPCs are clonal) and reduction of =1uninvolved Ig isotype (Only IgG, IgA and IgM will be considered) - Progressive increase in Serum M-protein level (evolving type of SMM) defined as an increase of Serum M-protein =10% in the last 12 months before enrolment in the study. This increase must be consistent from one to another sample (i.e., no decrease observed between 2 increased Serum M-protein values) - Both high-risk SMM and MM patients must have evidence of measurable disease in accordance with IMWG criteria - If patient with MM was eligible for ASCT, ASCT must have been performed, and patients cannot be enrolled until 3 months after ASCT - Patient should not be expected to require immediate, subsequent line of treatment for at least 2 months - Patient has not had reduction of clonal plasma cell markers for last two cycles (last two months if off treatment). If a patient had no reduction during the last two cycles of induction before ASCT, the patient can be enrolled, provided 3 months after ASCT - Following ASCT, the patient cannot be enrolled without having tried lenalidomide maintenance given at standard doses for at least two cycles, if the clonal markers had a reduction during the last 2 cycles of induction treatment. Lenalidomide will be stopped when entering the study - ECOG performance status 0-1 - Female patients of child-bearing potential (FCBP) must have negative serum pregnancy test at Screening and agree to use a highly effective method of contraception during treatment and for 3 months following last dose of drug. - Male patients must use an effective barrier method of contraception during treatment and for 3 months following the last dose if sexually active with a FCBP. - Ability to provide written informed consent and can understand and comply with the requirements of the study Exclusion Criteria: - Pregnant or lactating women or women without a pregnancy test at baseline (postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential) - Medical conditions such as but not limited to: 1. Any uncontrolled infection 2. Uncontrolled cardiac failure classification III or IV (NYHA) 3. Uncontrolled systemic and gastro-intestinal inflammatory conditions 4. History of adverse reactions to vaccines - Active malignancy with worse prognosis than multiple myeloma - Likely to require treatment intervention for multiple myeloma within two months of start of treatment with TG01/QS-21 - Known history of positive tests for HIV/AIDS, hepatitis B or C - Planned to receive yellow fever or other live (attenuated) vaccines during the course of study - Known hypersensitivity to QS-21. - Only participants who are able to consent will be included in the study.

Study Design


Intervention

Biological:
TG01
All participants will receive the same treatment as described under arm

Locations

Country Name City State
Norway Oslo Myeloma Center Oslo

Sponsors (2)

Lead Sponsor Collaborator
Oslo University Hospital Targovax ASA

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of participants with adverse events (AEs) An Adverse Event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Baseline until 30 days after last dose of study drug, up to approximately 3 years
Primary Percentage of participants discontinuing treatment secondary to treatment-related adverse events Percentage of participants discontinuing treatment secondary to treatment-related adverse events Up to approximately 3 years
Secondary Number of patients with Progression Free Survival (PFS) defined as the time from study treatment start to disease progression for every patient Baseline to 11 years
Secondary Concentration of TG01-specific T-cell specific cytokine production The immune response to TG01 will be measured by IFNg/TNFa ELISPOT or FluoroSpot quantifying the TG01 T-cell specific cytokine production. A positive immune response will be defined as a 2-fold higher mean spot number in experimental wells (with vaccine peptides) compared to control wells (medium) Baseline until end of study, assessed up to 11 years
Secondary Overall response rate per patient The proportion of patients who achieve partial response (PR) or better following at least one dose of study treatment Baseline to approximately 3 years
Secondary Overall Survival (OS) per patient The OS rate of patients receiving 1 or more study treatments Baseline until the end of study, assessed up to 11 years
Secondary Time to next treatment (TTNT) per patient defined as the time between the start date of the current treatment line and the start date of the next treatment line Baseline until the end of study, assessed up to 11 years
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1